MapLight Therapeutics, Inc. (MPLT) key performance indicators and operating metrics (2 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Approximately Randomized Participants in the Phase 2 IRIS Study (Autism Spectrum Disorder) | 161.00 | FY2026-Q1 |
| Expected Enrollment in the Phase 2 ZEPHYR Trial | 300.00 | FY2025-Q4 |
Back to MPLT overview · MPLT earnings · MPLT holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.